Can I Take Vitamin D with Low-Dose Naltrexone?

How Low-Dose Naltrexone Works

LDN occupies opioid receptors briefly each night, triggering a rebound increase in endogenous opioid production and downregulating microglial toll-like receptor 4 (TLR4) signaling. That anti-inflammatory mechanism is why clinicians prescribe it off-label for fibromyalgia, multiple sclerosis, Crohn's disease, and other inflammatory conditions. Younger et al. (2013) demonstrated in a randomized crossover trial (N=31) that LDN at 4.5 mg reduced fibromyalgia pain scores by 28.8% versus 18.0% for placebo (P<0.001), providing the most-cited efficacy signal in this population [1].

Pharmacokinetic Profile of LDN

Naltrexone is metabolized primarily by cytosolic dihydrodiol dehydrogenase to its active metabolite 6-beta-naltrexol. It does not meaningfully use CYP3A4, CYP2D6, or CYP1A2. Oral bioavailability sits near 5% to 40% due to extensive first-pass metabolism, with a plasma half-life of roughly 4 hours for naltrexone and 13 hours for 6-beta-naltrexol [2]. The FDA prescribing information for naltrexone 50 mg (ReVia) confirms this metabolic route [3].

Why the Low Dose Matters

Standard addiction-medicine doses (50 mg) fully block opioid receptors around the clock. LDN doses of 1.5 mg to 4.5 mg block receptors for only 4 to 6 hours, typically overnight, allowing the rebound upregulation effect. That transient blockade is the entire therapeutic rationale. Because the dose is so small, any theoretical drug-interaction signal present at 50 mg is further attenuated.

How Vitamin D Works

Vitamin D3 (cholecalciferol) undergoes hepatic hydroxylation to 25(OH)D via CYP2R1, then renal conversion to the active 1,25-dihydroxyvitamin D (calcitriol) via CYP27B1. Calcitriol binds the vitamin D receptor (VDR), a nuclear receptor present in immune cells, neurons, and musculoskeletal tissue. The Endocrine Society clinical practice guideline defines deficiency as 25(OH)D below 20 ng/mL and insufficiency as 20 to 29 ng/mL, with a treatment target of at least 30 ng/mL for most adults [4].

VDR Expression and Immune Modulation

VDR is expressed on T-lymphocytes, B-lymphocytes, macrophages, and dendritic cells. Calcitriol suppresses Th1 and Th17 differentiation while promoting regulatory T-cell activity. A 2017 meta-analysis of 25 randomized controlled trials (N=11,321) published in the BMJ found that vitamin D supplementation reduced the risk of acute respiratory tract infection by 12% overall, with the strongest protection in participants who were deficient at baseline (odds ratio 0.58, 95% CI 0.40 to 0.82) [5]. That immune-modulating action is the indirect reason vitamin D status is relevant in LDN patients.

CYP Enzymes Involved

The CYP2R1 and CYP27B1 enzymes responsible for vitamin D activation have no known interaction with naltrexone metabolism. This is not an opinion. The FDA drug interaction database and the NIH Office of Dietary Supplements both list no pharmacokinetic interaction between naltrexone and cholecalciferol or ergocalciferol [6].

Is There a Pharmacokinetic Interaction Between LDN and Vitamin D?

No pharmacokinetic interaction exists. The two compounds do not share metabolic enzymes, plasma protein binding sites, or transporter proteins. Neither compound alters the absorption, distribution, metabolism, or excretion of the other. The NIH Drug Interaction Database categorizes combinations like this as having no known mechanistic basis for a kinetic interaction [7].

This means you do not need to separate doses by time. Taking vitamin D in the morning and LDN at night is a common clinical pattern, but that schedule reflects LDN's preferred bedtime dosing for mechanistic reasons, not any requirement to avoid co-administration.

Is There a Pharmacodynamic Interaction?

This is the more clinically interesting question. LDN and vitamin D share overlapping immunomodulatory territory but act through entirely separate mechanisms. LDN suppresses TLR4-mediated microglial activation. Vitamin D suppresses Th17 differentiation and promotes regulatory T cells via VDR. The two effects may complement each other in autoimmune conditions, but no direct receptor competition or signal interference has been identified [8].

Potential Additive Benefit in Autoimmune Disease

In multiple sclerosis, both LDN and vitamin D have separately shown signals toward reduced relapse. A 2012 pilot trial of LDN in secondary progressive MS (N=40) published in the Annals of Neurology found no serious adverse events and modest quality-of-life improvement [9]. Separately, a Cochrane review of vitamin D in MS noted that 25(OH)D levels below 30 ng/mL correlate with higher relapse rates, though supplementation trials have not yet demonstrated definitive clinical benefit [10]. No trial has yet tested the combination prospectively. A framework for evaluating this combination in clinical practice is provided below.

No Antagonism Has Been Documented

Vitamin D does not stimulate opioid receptors or blunt LDN's rebound upregulation signal. LDN does not inhibit CYP2R1 or CYP27B1. No case report in PubMed documents a clinically meaningful adverse interaction between these two agents. The absence of antagonism matters because patients on LDN are frequently supplementing vitamin D precisely because their underlying condition depletes it.

Vitamin D Deficiency Is Highly Prevalent in LDN-Treated Conditions

Patients who take LDN are disproportionately vitamin D deficient for reasons unrelated to the drug itself. Understanding this baseline risk shapes the monitoring conversation.

Fibromyalgia

A 2014 systematic review and meta-analysis in Pain Physician found that patients with fibromyalgia had significantly lower serum 25(OH)D levels than healthy controls, with a weighted mean difference of -5.58 ng/mL (P<0.001) [11]. Deficiency prevalence ranged from 30% to 60% across included cohorts.

Multiple Sclerosis

A prospective study of 469 MS patients found that 79% had 25(OH)D below 30 ng/mL at enrollment, with a mean level of 18.7 ng/mL [12]. The National Multiple Sclerosis Society recommends routine vitamin D screening for all MS patients and supplementation when deficient [13].

Inflammatory Bowel Disease

Crohn's disease impairs fat-soluble vitamin absorption, and LDN is being studied as an adjunct in Crohn's. A randomized trial of LDN in pediatric Crohn's (N=40) published in the Journal of Clinical Gastroenterology found a 33% remission rate versus 0% for placebo [14]. Vitamin D deficiency affects 35% to 75% of IBD patients in published cohort studies [15].

Dosing and Administration Guidance

No dose separation is required. Standard clinical practice when prescribing both agents is straightforward.

LDN Dosing Protocol

LDN must be compounded, as no FDA-approved low-dose formulation exists. The typical titration schedule starts at 1.5 mg nightly for two weeks, advances to 3 mg nightly for two weeks, and then reaches the target of 4.5 mg nightly. Some protocols use 1 mg increments every one to two weeks to minimize vivid dreams, the most commonly reported side effect during titration [1].

LDN should be taken between 9 PM and 3 AM to align the receptor-blockade window with the body's peak endogenous opioid production overnight. The Low Dose Naltrexone Research Trust and prescribing clinicians generally advise consistent bedtime dosing [16].

Vitamin D Dosing Protocol

The Endocrine Society recommends 1,500 to 2,000 IU daily for adults at risk of deficiency, rising to 6,000 to 10,000 IU daily for 8 weeks when treating confirmed deficiency (25(OH)D below 20 ng/mL), followed by maintenance of 1,500 to 2,000 IU [4]. Vitamin D3 (cholecalciferol) raises serum levels more effectively than D2 (ergocalciferol) at equivalent doses. Taking vitamin D with the largest fat-containing meal of the day increases absorption by approximately 32%, based on a pharmacokinetic study of 17 participants published in the Journal of Bone and Mineral Research [17].

Timing Relative to Each Other

Because LDN is taken at night and vitamin D is best absorbed with a fatty meal, most patients naturally separate the doses by many hours. That separation is convenient, not mandatory. No interaction data require it.

Monitoring Recommendations

Both compounds require periodic lab monitoring, though the monitoring is driven by each drug's own safety profile rather than interaction risk.

For Vitamin D

Check serum 25(OH)D and serum calcium at baseline and again at 8 to 12 weeks after any dose change, then every 6 months once stable. The Endocrine Society defines vitamin D toxicity as 25(OH)D above 150 ng/mL; hypercalcemia typically appears above 200 ng/mL [4]. At standard supplementation doses of 1,000 to 5,000 IU daily, toxicity is rare but possible in patients with granulomatous disease (sarcoidosis, tuberculosis) who produce calcitriol extra-renally.

For LDN

LDN carries no specific lab monitoring requirement at low doses, but liver function tests at baseline are prudent given that standard-dose naltrexone carries a hepatotoxicity warning. The FDA label for naltrexone 50 mg notes that doses above 50 mg/day have been associated with hepatocellular injury [3]. At 4.5 mg daily, this risk is considered negligible, but baseline LFTs provide a safety anchor.

Combined Monitoring Schedule

A practical schedule for patients on both agents: baseline 25(OH)D, calcium, and LFTs at the time of LDN initiation; repeat 25(OH)D and calcium at 8 to 12 weeks; then every 6 months. No interaction-specific lab is needed.

What If You Are Already Taking Both?

If you are already taking vitamin D alongside LDN and tolerating both without symptoms, no change is indicated. Signs that would prompt a reassessment include hypercalcemia symptoms (nausea, constipation, polyuria, confusion), which are unrelated to LDN but can develop with excessive vitamin D intake, and vivid dreams or sleep disruption during the LDN titration phase, which are related to LDN alone [1].

No interaction makes stopping vitamin D necessary when starting LDN. No interaction makes stopping LDN necessary when adding vitamin D. If anything, correcting deficiency before or during LDN initiation supports the immune environment in which LDN operates.

Special Populations

Patients With Granulomatous Disease

Patients with sarcoidosis, tuberculosis, or certain lymphomas produce activated 1,25-dihydroxyvitamin D independently of renal regulation. For these patients, vitamin D supplementation carries higher hypercalcemia risk regardless of LDN status. The American Thoracic Society advises caution with vitamin D supplementation in sarcoidosis and recommends checking 1,25(OH)2D (calcitriol) rather than relying solely on 25(OH)D [18].

Patients on Opioid Therapy Transitioning to LDN

Patients switching from opioid analgesics to LDN must clear opioids before starting LDN to avoid precipitated withdrawal. The standard washout is 7 to 10 days for short-acting opioids and up to 14 days for methadone or buprenorphine. Vitamin D requires no adjustment during this transition. The Substance Abuse and Mental Health Services Administration (SAMHSA) provides transition guidance for naltrexone initiation [19].

Pediatric and Adolescent Patients

Pediatric LDN trials exist (Crohn's, N=40 as noted above [14]), and pediatric vitamin D requirements are well established by the American Academy of Pediatrics. No pediatric-specific interaction data exist. Pediatric dosing of both compounds should be supervised by a physician.

Pregnancy and Lactation

LDN is not FDA-approved and has minimal safety data in pregnancy. Vitamin D at 600 to 2,000 IU daily is considered safe in pregnancy per the American College of Obstetricians and Gynecologists (ACOG) [20]. Clinicians should weigh LDN risk against benefit on an individual basis during pregnancy; vitamin D should generally be continued.

Drug-Supplement Context: Why This Combination Is Commonly Prescribed

Clinicians who prescribe LDN often do so for patients whose underlying condition depletes vitamin D, whose disease course correlates with vitamin D status, or who have already been advised to supplement. Rather than representing a risky combination requiring caution, this pairing is one of the more rational ones in integrative clinical practice.

A 2020 narrative review in Frontiers in Pharmacology summarized evidence across 18 trials and case series for LDN across autoimmune conditions and noted that nutritional optimization, including vitamin D repletion, appeared in the management protocols of several contributing centers [8]. That pattern reflects clinical consensus, even in the absence of a head-to-head combination trial.

The absence of an FDA-approved indication for LDN means patients rely on compounding pharmacies and clinician expertise. Quality of the compounded product matters. PCAB-accredited or state-board-inspected compounding pharmacies are the standard recommendation, as filler choice (naltrexone in distilled water versus a calcium carbonate base) can theoretically affect absorption, though no trial has formally compared formulations.